Alteration of Lipid Profile Between Subclinical Hypothyroidism and Well-Matched Controls: A Meta-Analysis

Abstract

In previous studies, subclinical hypothyroidism (SCH) has been associated with altered lipid profiles. However, since the discrepancy between these study results may reside in the great heterogeneity of the populations studied, this relationship is controversial. This study aimed to explore the changes in total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c) between subclinical hypothyroidism (SCH) and well-matched euthyroid (EU) groups. Multiple databases were searched for publications before December 1, 2021, including cross-sectional studies on the association between SCH and lipid profile matched by age, gender, and BMI. Twenty-five articles with 3347 participants were included for meta-analysis. The results showed that the TC, TG, and LDL-c levels of the SCH groups were higher than the EU groups (TC, SMD=0.49, 95% CI 0.27, 0.71, p<0.001) (TG, SMD=0.43, 95% CI 0.21, 0.64, p<0.05 ) (LDL-c, SMD=0.75, 95% CI 0.46, 1.03, p<0.001 ). The HDL-c levels of the SCH group were lower than the control group (SMD=–0.53, 95% CI –0.81, –0.25, p<0.05). SCH has a larger impact on LDL-c than the other three indicators. After subgroup analyses, there was a larger impact on lipid alteration in the subgroup of TSH>10 μIU/ml, especially on LDL-c. This study found that SCH was associated with altered lipid profiles. Appropriate clinical treatment may be needed to prevent dyslipidemia and related diseases.

Key words

subclinical hypothyroidism - thyroid - lipid profiles - dyslipidemia - meta-analysis

Publication History

Received: 13 October 2022

Accepted after revision: 26 April 2023

Accepted Manuscript online:
26 April 2023

Article published online:
02 June 2023

• References

• 1 Ross DS. Serum thyroid-stimulating hormone measurement for assessment of thyroid function and disease. Endocrinol Metab Clin North Am 2001; 30: 245-264 vii
• 2 Delitala AP, Fanciulli G, Maioli M. et al. Subclinical hypothyroidism, lipid metabolism and cardiovascular disease. Eur J Intern Med 2017; 38: 17-24
• 3 Biondi B, Cappola AR, Cooper DS.. Subclinical hypothyroidism: a review. JAMA 2019; 322: 153-160
• 4 Surks MI, Ortiz E, Daniels GH. et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228-238
• 5 Liu HH, Li JJ. Aging and dyslipidemia: a review of potential mechanisms. Ageing Res Rev 2015; 19: 43-52
• 6 Kopin L, Lowenstein C.. Dyslipidemia. Ann Intern Med. 2017. 167. ITC81-ITC96
• 7 Raitakari OT, Juonala M, Kähönen M. et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the cardiovascular risk in young Finns study. JAMA 2003; 290: 2277-2283
• 8 Magnussen CG, Raitakari OT, Thomson R. et al. Utility of currently recommended pediatric dyslipidemia classifications in predicting dyslipidemia in adulthood: evidence from the childhood determinants of adult health (CDAH) study, cardiovascular risk in young Finns study, and Bogalusa heart study. Circulation 2008; 117: 32-42
• 9 Davis PH, Dawson JD, Riley WA. et al. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine study. Circulation 2001; 104: 2815-2819
• 10 Klag MJ, Ford DE, Mead LA. et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993; 328: 313-318
• 11 Pencina KM, Thanassoulis G, Wilkins JT. et al. Trajectories of non-HDL cholesterol across midlife: implications for cardiovascular prevention. J Am Coll Cardiol 2019; 74: 70-79
• 12 Cappola AR, Ladenson PW.. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003; 88: 2438-2444
• 13 Pearce EN.. Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab 2012; 97: 326-333
• 14 Vierhapper H, Nardi A, Grösser P. et al. Low-density lipoprotein cholesterol in subclinical hypothyroidism. Thyroid 2000; 10: 981-984
• 15 Janovsky CCPS, Bittencourt MS, Goulart AC. et al. Unfavorable triglyceride-rich particle profile in subclinical thyroid disease: a cross-sectional analysis of ELSA-Brasil. Endocrinology 2021; 162: bqaa205
• 16 Ruoxuan P, Hong Z, Qin X. et al. Correlation analysis of subclinical hypothyroidism and dyslipidemia in women in Changchun area. Mater Child Health Care China 2018; 33: 5328-5330
• 17 Liu XL, He S, Zhang SF. et al. Alteration of lipid profile in subclinical hypothyroidism: a meta-analysis. Med Sci Monit 2014; 20: 1432-1441
• 18 Li F, Wan S, Zhang L. et al. A meta-analysis of the effect of iodine excess on the intellectual development of children in areas with high iodine levels in their drinking water. Biol Trace Elem Res 2021; 200: 1580-1590
• 19 Wan S, Jin B, Ren B. et al. The Relationship between high iodine consumption and levels of autoimmune thyroiditis-related biomarkers in a Chinese population: a meta-analysis. Biol Trace Elem Res 2020; 196: 410-418
• 20 Duntas LH, Brenta G.. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am 2012; 96: 269-281
• 21 Kotwal A, Cortes T, Genere N. et al. Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis. J Clin Endocrinol Metab 2020; 105: dgaa672
• 22 McDermott MT, Ridgway EC.. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab 2001; 86: 4585-4590
• 23 Bindels AJ, Westendorp RG, Frölich M. et al. The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for case-finding?. Clin Endocrinol (Oxf) 1999; 50: 217-220
• 24 Choi JW, Choi HS.. The regulatory effects of thyroid hormone on the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Endocr Res 2000; 26: 1-21
• 25 Sasaki S, Kawai K, Honjo Y. et al. Thyroid hormones and lipid metabolism. Nihon Rinsho Jpn. J Clin Med 2006; 64: 2323-2329
• 26 Valdemarsson S, Hansson P, Hedner P. et al. Relations between thyroid function, hepatic and lipoprotein lipase activities, and plasma lipoprotein concentrations. Acta Endocrinol 1983; 104: 50-56
• 27 Lam KS, Chan MK, Yeung RT.. High-density lipoprotein cholesterol, hepatic lipase and lipoprotein lipase activities in thyroid dysfunction--effects of treatment. Quart J Med 1986; 59: 513-521
• 28 Cohen J. A power primer. Psychol Bull 1992; 112: 155-159
• 29 Duntas LH, Mantzou E, Koutras DA.. Circulating levels of oxidized low-density lipoprotein in overt and mild hypothyroidism. Thyroid 2002; 12: 1003-1007
• 30 Zhong Q, Zhao S, Yu B. et al. High-density lipoprotein increases the uptake of oxidized low density lipoprotein via PPARγ/CD36 pathway in inflammatory adipocytes. Int J Biol Sci 2015; 11: 256-265
• 31 Grundy SM, Cleeman JI, Merz CN. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239
• 32 Rodondi N, den Elzen WP, Bauer DC. et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010; 304: 1365-1374
• 33 Duntas LH, Wartofsky L.. Cardiovascular risk and subclinical hypothyroidism: focus on lipids and new emerging risk factors. What is the evidence?. Thyroid 2007; 17: 1075-1084